Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161911 · ClinicalTrials.gov registry record
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
A clinical trial of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,426
- Enrollment target
- 1
- Study location
NCT04161911: Completed study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
NCT04161911 is a study of Hepatocellular Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,426 participants, above the 248-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (475% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04161911, a study of Hepatocellular Carcinoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,426 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
Primary Outcome
Nivolumab second and third lines of therapy will be described including prior lines of therapy, duration of nivolumab therapy and time from aHCC diagnosis date to first nivolumab treatment
Conditions Studied
Study Locations (1)
New Jersey
- Bristol Myers Squibb, CORDS Research - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,426 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2018-11-19 |
What the finished NCT04161911 record still lists
NCT04161911 is an observational study that tracks outcomes without assigning an intervention. Its 1,426 participants enrollment target places it among the larger protocols in the corpus, above the 248-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (475% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04161911 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04161911 about?
NCT04161911 is a clinical study titled "A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy". A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
What is the current status of trial NCT04161911?
This trial is currently completed. The enrollment target is 1,426 participants. The study started on 2018-10-29. Estimated completion is 2018-11-19.
What conditions does trial NCT04161911 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
Who is sponsoring clinical trial NCT04161911?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04161911 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04161911's enrollment target sits among peer trials
1,426 5th of 145 higher than 141 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI